Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.

J Clin Oncol

Mehmet Sitki Copur, Dron Gauchan, Ryan Ramaekers, David Crockett, and Douglas Clark, Catholic Health Initiatives St. Francis Cancer Treatment Center, Grand Island, NE.

Published: March 2017

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7125DOI Listing

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
4
chemotherapy primary
4
primary debulking
4
debulking surgery
4
surgery stage
4
stage iiic
4
iiic ovarian
4
ovarian cancer
4
neoadjuvant
1
primary
1

Similar Publications

Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.

Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.

View Article and Find Full Text PDF

Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. In the current study, we performed an unbiased Reverse Phase Protein Array (RPPA) on TNBC cells treated with chemotherapy compounds and found a leading significant increase of phosphor-AURKA/B/C, AURKA, AURKB, and PLK1, which fall into the mitotic kinase group.

View Article and Find Full Text PDF

Objectives: Liver transplant (LT) is an effective treatment for hepatocellular carcinoma (HCC) in appropriately selected patients. Locoregional therapy (LRT) is often performed to extend a patient's eligibility for LT. Imaging has a modest sensitivity of approximately 40-77% for detecting pathologically viable HCC in post-LRT patients.

View Article and Find Full Text PDF

[Clinical characteristics and prognosis of ovarian juvenile granulosa cell tumors].

Zhonghua Fu Chan Ke Za Zhi

January 2025

Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100021, China.

To analyze the clinical characteristics, treatments, and prognosis of patients with ovarian juvenile granulosa cell tumor (JGCT). Clinical and pathological data, and follow-up information of 34 patients diagnosed with JGCT from 2000 to 2021 were collected from the surveillance, epidemiology, and end results (SEER) database. A retrospective analysis was conducted to summarize the patients' clinical and pathological characteristics, treatments, and prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!